




[12] Patent

[11] Patent No.: GC 0000113	Number of the Decision to Grant the Patent: 5/224
[45] Date of Publishing the Grant of the Patent: 29/06/2005 4/2005	Date of the Decision to Grant the Patent: 15/03/2005
[21] Application No.: GCC/P/1999/381 [22] Filing Date: 24/11/1999 [30] Priority: [31] Priority No. [32] Priority date [33] State 9825988.0 27/11/1998 GB [72] Inventors: 1- Christopher Ian Dallman, 2- Ronald James Ogilvie [73] Owner: Pfizer Inc, 235 East 42nd Street, New York, New York 10017, USA [74] Agent: Nasser Ali Kadasa	[51] Int.Cl. ⁷ : C07D 403/06; A61K 31/40; A61P 25/06 [56] Cited Documents: - WO 9606842 A (PFIZER LTD; PFIZER RES & DEV (IE); PFIZER (US); HARDING VALERIE DE) 07 March 1996 - WO 9827089 A (ALLELIX BIOPHARMA) 25 June 1998 - WO 9839327 A (MARAGNI PAOLO; CIMAROSTI ZADEO (IT); GLAXO WELLCOME SPA (IT)) 11 September 1998

[54] ELETRIPTAN HYDROBROMIDE MONOHYDRATE

[57] Abstract: The present invention provides eletriptan hydrobromide monohydrate of the formula (I):



together with processes for preparing, uses of, and compositions containing, said monohydrate.

No. of claims: 16

No. of figures: 7